In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on BioLife Solutions (BLFS – Research Report). The company’s shares closed last Friday at $19.22.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Omnicell, and Repligen. According to TipRanks, Hewitt has an average return of 5.8% and a 44.90% success rate on recommended stocks.
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $30.33.
See Insiders’ Hot Stocks on TipRanks >>
BLFS market cap is currently $835.8M and has a P/E ratio of -5.64.
Based on the recent corporate insider activity of 143 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
